Clinical trial
Rasburicase for Hyperuricemia
NCT00290992 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00290992 |
|---|---|
| Title | Rasburicase for Hyperuricemia |
| Official title | Open-Label, Multi-Center Study of SR29142 as Uricolytic Therapy/Prophylaxis for Hyperuricemia in Pediatric Patients With Newly Diagnosed Hematological Malignancies at High Risk for Tumor Lysis Syndrome |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Nutritional and Metabolic Diseases |
| Intervention type | Drug |
| Interventions | rasburicase (SR29142) |
| Enrollment | 30 |
| Start date | Jun 1, 2005 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Feb 13, 2006 |
| Last update posted | Mar 30, 2009 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: